Alteogen signs deal with Novartis worth up to 4.4 trillion won for subcutaneous formulations

▤ Summary

Alteogen signed a deal with Novartis worth up to 4.4 trillion won for subcutaneous formulations. The agreement points to a major collaboration in drug delivery and life sciences commercialization. The article text does not provide operational details beyond the headline-level transaction. No product launch, acquisition, or personnel change is described.

▦ Linked Companies